Could Metformin Reduce Cancer Death Risk?

Metformin, one of the most widely prescribed diabetes drugs, may have a new, hidden benefit: reducing the risk of dying from some cancers in postmenopausal women with type 2 diabetes, HealthDay reports.

These findings are from a new study in International Journal of Cancer, which found that for women with type 2 diabetes and cancer who are taking Metformin, the risk of dying from cancer was the same as diabetes-free women with cancer. In women with cancer and diabetes who weren’t taking Metformin, their risk of dying from cancer appeared to be  45% higher.

Read complete story.

You may also like

  • VIDEO: Exposure to High-Fat Diet In Utero Reprograms Liver, Leads to Metabolic Disease

    In utero exposure to a high-fat diet reprograms the liver, leads to long-term gene dysregulation, and ultimately to metabolic disease, according to the results of an animal study recently published in Endocrinology. Researchers led by Maureen J. Charron, PhD, of Albert Einstein College of Medicine in the Bronx, N.Y., point out that it’s already known…

  • Endocrine Society Joins JDRF’s Coverage2Control Campaign

    The Endocrine Society has signed on as a partner to JDRF’s Coverage2Control campaign, calling on insurance companies to provide better health coverage for the 1.25 million Americans living with type 1 diabetes. Coverage2Control, launched in May, has the support of more than 52,000 people who have signed JDRF’s petition urging insurance companies to provide coverage…